BlackRock, Inc. Amends Schedule 13G/A for Fulcrum Therapeutics Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for Fulcrum Therapeutics Inc., reporting a decrease in its ownership to 6.0% of the common stock. The filing indicates that BlackRock beneficially owns 3,270,322 shares, with sole voting power over 3,180,792 shares and sole dispositive power over all 3,270,322 shares. The amendment reflects changes in ownership as of September 30, 2025, and was filed on October 17, 2025. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.